Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSALON: Additive Benefits of Semaglutide for Open-Angle Glaucoma
2022-004142-35Phase 4Active
- Sponsor
- Rigshospitalet
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, single-arm trial of semaglutide in open-angle glaucoma (OAG) and Glaucoma, sponsored by Rigshospitalet. Primary endpoint: Inner retinal function change (PhNR of ERG). Started Feb 2023; status: active.
02
Drugs
03
Conditions
open-angle glaucoma (OAG)Glaucoma
Beyond the preview
Go deeper on 2022-004142-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004142-35.